Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma
Wenzel, Sally E., MD, FAAAAI, Hopkins, Robert, Saunders, Michael, Dr, Chantry, David, Anderson, Lisa, Aitchison, Roger, Eberhardt, Christine, Bell, Stacie, Cole, Jeremy, Dr, Wolfe, James, Dr, Spector, Sheldon L., Dr, Sher, Lawrence D., Dr, Kerwin, Edward M., Dr, Burgess, Larry, Dr
Published in Journal of allergy and clinical immunology (01.02.2014)
Published in Journal of allergy and clinical immunology (01.02.2014)
Get full text
Journal Article